OneDigital NorCal HR Consulting

Big moves in gut health: Supergut just landed new funding and a new CEO— Tracey Warner Halama , former CEO of Vital Proteins. Curious what’s next? Read the article below:

Recent policy shifts, including the announcement of sweeping new #tariffs, are sending ripple effects across global markets, business operations, and employer strategies. And while the headlines often focus on market volatility and trade balances, HR leaders are beginning to feel the pressure in far more immediate ways: rising costs, strained budgets, and increased employee anxiety. As you prepare to lead your organization through this period of uncertainty, here are 4 key considerations to keep in mind: https://hubs.ly/Q03j40rF0 #pharma #employeebenefits

Today, we are excited to announce our $90 million Series C financing led by a new investor, Deep Track Capital (https://lnkd.in/gKyRaeVS), with participation from new investors including Vida Ventures, LLC, Sanofi Ventures (https://lnkd.in/geS9GiU3), and Mirae Asset Capital Life Science. Existing investors also joined this round, including Frazier Life Sciences, venBio, Goldman Sachs Alternatives (https://lnkd.in/gZVKxPpm), Nextech Invest, Cormorant Asset Management, LP, EcoR1 Capital, LLC, Marshall Wace, and Illumina Ventures. We also welcome Rebecca Luse, Managing Director at Deep Track Capital, to our Board of Directors. At Attovia, we are building an entirely new type of biologics with our #ATTOBODY technology—multi-specifics with breakthrough efficacy—with the potential of becoming the next generation modality of choice. Proceeds will be used to advance our lead first-in-class assets, ATTO-1310 in chronic #pruritus of unknown origin (#CPUO) and bispecific ATTO-3712 in atopic dermatitis (#AD) to proof-of-concept as well expand our pipeline of multi-specifics for patients suffering from immune-mediated disorders, including inflammatory bowel disease (#IBD) and others. Learn more: https://lnkd.in/g9xCCfKY #immunology #inflammation

We're #hiring a new Vice President, Translational Biology in South San Francisco, California. Apply today or share this post with your network.

We are pleased to share that the FDA has cleared our IND application for EPI-321 in the United States! EPI-321 is designed to address the root cause of FSHD by restoring epigenetic regulation of the D4Z4 region and silencing toxic DUX4 gene expression. Our first-in-human U.S. clinical trial is expected to begin later this year.    Read more in today’s press release here: https://bit.ly/3FU4HsQ   #FSHD #Epigenetics #Biotech #Epicrispr #GeneticMedicines  

Are you ready to make a significant impact in the field of oncology? Apertor Pharmaceuticals, Inc., based in Alameda, CA, is pioneering the development of novel molecular glues for therapeutic applications. Our innovative compounds, known as Interceptors, are heterobifunctional (HBF) therapeutics designed to target disease-causing protein complexes. Position: Associate Director/Director/Senior Director of Pharmaceutical Development Location: Alameda, CA (Hybrid role near Oakland Airport) We are seeking a dynamic and skilled leader to manage pharmaceutical development across our heterobifunctional drug development programs. Reporting directly to the CEO, you will play a crucial role in implementing and overseeing CMC development and manufacturing activities. You will also manage a network of consultants and Contract Development and Manufacturing Organization (CDMO) partners to drive our efforts in developing cutting-edge therapeutics. Key Responsibilities: Lead pharmaceutical development, including dosage form selection, formulation development, process optimization, and scale-up activities. Ensure robust, cost-effective, and scalable manufacturing processes to support GMP drug product development. Direct CMC and cross-functional project teams to ensure on-time supply of drugs for non-GLP toxicology studies, IND-enabling activities, and clinical trials. Feel free to reach out to me for more information and view the job opening at: https://lnkd.in/gsC5vJCd Note: No agency assistance is needed at this time.

Abdera Therapeutics is seeking a Sr. Clinical Study Lead for our 320 program. The ideal candidate will have demonstrated expertise in overseeing Phase I oncology studies, collaborating closely with development, managing vendors, and facilitating site qualification. Prior leadership experience is required, accompanied by strong interpersonal abilities. This position offers a hybrid work setup, with 3 days per week required onsite for individuals residing in the SF Bay Area. Our office is situated in South San Francisco. Remote work may be considered for candidates located preferably on the West Coast. For more details about this opportunity, please refer to the link below. We welcome your interest and inquiries. [Link to the job posting] (https://lnkd.in/gh5AEbcT)